It has been reported that the majority of life on earth occupies a fraction of the world's surface, termed the 'ocean fringe', and it is to this species-rich environment that researchers are increasingly turning in order to identify and isolate new drugs [1, 2] . The value of natural products from marine species, such as sponges and tunicates, or their associated micro-organisms, has been recognized for over half a century, but it is only in recent years there has been a renewed interest in this potential source of new medicines. Despite the obvious challenges in obtaining sufficient material for pre-clinical and clinical studies there have been some notable successes in the areas of chronic pain (e.g. ω-Conotoxin VIIA, Ziconotide) and potential anti-cancer therapies (e.g. Ecteinascidin 743, Trabectedin) [1, 2] . The types of molecule that have been identified as potential drugs or lead compounds typically fall into several chemical classes, which include linear and cyclic peptides, depsipeptides, diterpenes, alkaloids and pyrrolocarbazoles, that often represent secondary metabolites. The advantage of natural products is that they occupy complex chemical and structural space, which offers a cornucopia of molecules to screen for desirable properties. However, this complexity also poses significant challenges as these compounds are often in limited supply and complete synthesis may be impractical.
NRs (nuclear receptors) represent a diverse superfamily of ligand-activated and orphan transcription factors that play fundamental roles in a disparate array of biological processes from development to metabolism to reproductive health [3] . They also represent well-validated drug targets for some of the major health concerns facing the developed world, including metabolic syndrome and associated disorders and hormone-dependent cancers. A major goal in recent drug development programmes has been to produce ligands which exhibit agonist or antagonist activity in a tissue as well as a receptor-selective manner; the aim being to reduce adverse side effects and, in the case of certain cancers to combat hormone resistance. The question is can natural products, in particular those from marine environments, provide novel drugs or lead compounds that would meet these criteria?
In a paper published in this issue of the Biochemical Journal, Wang et al. [4] describe the identification and characterization of an agonist for the RAR [RA (retinoic acid) receptor] isolated from the sponges Luffariella sp. and Fascaplysinopsis. The compound, luffariellolide, is a sesterterpene with some structural similarity to all-trans-RA, but containing a unique γ -hydroxybutenolide group at the end of the hydrophobic tail ( Figure 1 ). RARs bind derivatives of vitamin A, notably all-trans-RA and 9-cis-RA and typically regulate networks of target genes as heterodimers with another NR, the RXR (retinoid X receptor) [5, 6] . In the absence of an RAR ligand the RAR-RXR complex is thought to negatively regulate gene transcription, whereas binding of RA to the RAR switches the complex to positively regulating gene expression or, in the case of some genes, repression of transcription ( Figure 1 ). RARs exist as three distinct subtypes, α (NR1B1), β (NR1B2) and γ (NR1B3), as well as subtype isoforms, which collectively contribute to both redundancy and complexity in the response to both natural and synthetic ligands [5, 6] .
RA signalling is important during development, in immunity, reproduction and tissue homoeostasis, and retinoids have been used therapeutically in the treatment of skin diseases (severe acne) and cancer [6, 7] . However, there are major concerns with these treatments such as the occurrence of RA resistance and the known teterogenic action and toxicity of natural and synthetic retinoids. There is therefore a clear need to continue to develop new modulators of RAR signalling, which may show less adverse side effects. The Li laboratory set out to identify agonists for RARs present in a marine natural products library [4] . Using a cell-based bioassay they could show that luffariellolide was a selective agonist for all three of the RAR subtypes, but not steroid or other NRs, including the partner RXRα. Of particular significance they report the crystal structure of luffariellolide bound to the LBD (ligand-binding domain) of RARα and compare this with the natural agonist all-trans-RA. The structure reveals that luffariellolide and all-trans-RA occupy a similar ligandbinding pocket, but highlights some key residues important for the binding of the sesterterpene molecule. Strikingly the structure also shows a covalent bond formed from a cysteine residue (amino acid 235 in RARα) and the ketone on the unique γ -hydroxybutenolide group of luffariellolide. The covalent interaction of the ligand with the receptor was confirmed by mass spectrometry and mutation of the cysteine residue, which is conserved in all three of the RAR subtypes. In different cell culture models the authors demonstrate that luffariellolide could reduce cell proliferation and induce known RA-inducible genes in a receptor-dependent manner. Of note is the observation that in a RA-resistant cell line, HCT-16, luffariellolide was able to function as an RAR agonist, reducing cell proliferation and switching on target genes. The authors speculate that the unique binding of luffariellolide to the RAR may account for this reversal of the RA-resistant phenotype. In future studies it will be worth investigating if this molecule can act in a suitable in vivo disease model. Although the bulkier luffariellolide molecule causes some local distortion of the helical structure of the LBD, it clearly does not adversely have an impact on the LBD surface that is important for co-regulatory protein binding. The presence of an alcohol group, opposite the ketone moiety, may provide an opportunity for chemical modification of luffariellolide to create a panel of ligands that would cross-link with the receptor, but alter the structure such that they act as antagonists and switch off the RAR response. At the very least, new tools to probe RAR activity may be produced. It will be of interest to determine if the covalently liganded receptor has an altered turnover rate in target cells or increased occupancy on DNA-response elements compared with the natural ligand, and so provide further mechanistic insights into luffariellolide action. Of more general consideration is whether the design of ligands to covalently bind to cognate NRs would have wider significance in the design of novel agonist and antagonist drugs? Plants have longed proved a rich source of natural products that act as agonists or antagonists for NRs. Examples include the isoflavone genistein, which activates oestrogen receptor β (NR3A2) [8] , lupenol [9] and N-butylbenzene-sulfonamide [10] , which antagonize the AR (androgen receptor; NR3C4), and the tea catechin EGCG (epigallocatechin-3-gallate), which has been found to antagonize the AR [11] , but activate the farnesoid X receptor (NR1H4/5) [12] . Now that marine organisms are also providing compounds that modulate NR activity, including psammaplin A from the sponge Pseudoceratina rhax which activates PPARγ (peroxisome-proliferator-activated receptor γ NR1C3) [13] and a group of glycerol ethers (niphatenones) from the sponge Niphates digitalis which antagonize AR activity [14] . Interestingly niphatenone B [14, 15] , a group of chloronated peptides, termed sintokamides, from the sponge Dysidea sp. and a synthetic molecule (Bisphenol A diglycidic ether), isolated from a sponge extract, all act on the receptor N-terminal domain, not the LBD. These are crucial observations because they demonstrate the possibility of targeting regions out with the traditional LBD with compounds that can modulate NR activity (reviewed in [16] ). The advantage of such approaches are likely to be 2-fold: first, it will directly circumvent hormone resistance arising from compounds binding to the LBD; and secondly, it may lead to combination therapies involving lower doses of say an antagonist and so help reduce side effects.
It seems probable that future drug discovery programmes by pharmaceutical companies will continue to depend on combinatorial chemistry and high-throughput screening, together with, perhaps, fragment-based and structure-led drug discovery approaches. However, it is becoming increasingly difficult to ignore the data being generated showing the potential of natural products from plants, micro-organisms and the marine environment to provide new medicines. The development of natural products into viable drugs, or drug leads, has been held up as a model of how academic researchers and the pharmaceutical industry can productively collaborate [1] . It is therefore reasonable to expect that such interactions will continue to be essential if the potential of the 'ocean fringe' in drug discovery is to be realized.
